PMN insider trading
NasdaqCM HealthcareProMIS Neurosciences Inc.: insider trade history from SEC Form 4 filings.
About ProMIS Neurosciences Inc.
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's Disease; PMN267 for treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
Company website: www.promisneurosciences.com
PMN insider activity at a glance
FilingIQ tracks 59 insider transactions for PMN in filings since Jul 12, 2022. The most recent transaction is dated Aug 5, 2026.
Across the full history, 31 open-market purchases
and 1 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on PMN insider trades is 59.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest PMN Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for PMN?
- FilingIQ tracks 59 Form 4 insider transactions for PMN (ProMIS Neurosciences Inc.), covering filings from Jul 12, 2022 onwards. 1 of those are dated within the last 90 days.
- Are PMN insiders net buyers or net sellers?
- Across the full Form 4 history for PMN, 31 transactions (53%) were open-market purchases and 1 (2%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does PMN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is PMN in?
- ProMIS Neurosciences Inc. (PMN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $34.63M.
Methodology & sources
Every PMN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.